Three months of Xadago (safinamide) as an add-on therapy lessened symptoms of rapid eye movement sleep behavior disorder (RBD) in people with Parkinson’s disease, a pilot study in patients reported. The study, “Effects of safinamide on REM sleep behavior disorder in Parkinson disease: A randomized, longitudinal,…
Low-frequency deep brain stimulation (DBS) may help to ease balance problems due to postural instability in people with Parkinson’s disease, a small clinical trial reported. But patients with significant tremor prior to starting DBS may not find the treatment tolerable, because it can lead to the re-emergence of…
Genetic variations in the gene SNCA are tied to an increased risk of Parkinson’s disease (PD) among Latinos, according to a recent analysis. Also, Latinos with African ancestry are less likely to develop Parkinson’s. The analysis is “the most comprehensive examination of PD genetics in this population [Latinos] to…
In mice with a harmful mutation in the leucine-rich repeat protein kinase 2 (LRRK2) gene, one of the most common genetic causes of Parkinson’s disease, treatment with a small molecule compound restored the recycling of damaged mitochondria — the cells’ powerhouses — from dopamine-producing nerve cells. A failure…
AbbVie has selected two drug candidates — both targeting enzymes known as DUBs — for further development as possible Parkinson’s disease treatments, as part of the company’s ongoing collaboration with Mission Therapeutics. “We are delighted to have reached this next major milestone in our collaboration with AbbVie and…
A new hydrogel matrix appears to ease the delivery of therapeutic stem cells into the brain, a necessary step in potentially using these cells to treat Parkinson’s disease. In animal models, this hydrogel was found to provide a safe scaffold for stem cells to differentiate into dopamine-producing nerve cells —…
A $20,000 Parkinson’s Foundation community grant will help to keep the American Dance Festival’s (ADF) Parkinson’s Movement Initiative (PMI) going for a fifth year. The program, founded by ADF in 2017 with NC Dance for Parkinson’s, and Poe Wellness Solutions, is free for Parkinson’s disease (PD)…
A Michael J. Fox Foundation (MJFF) research fellow is leading a study into the role of social determinants in medical mistrust and the lack of clinical trial participation by people with diseases such as Parkinson’s who belong to racial, ethnic and social minority groups. Paris Adkins-Jackson’s study, titled “…
Clene Nanomedicine‘s investigational oral Parkinson’s treatment, CNM-Au8, safely and significantly increased energy metabolism in the brains of patients taking part in the Phase 2 REPAIR clinical trials, top-line results show. Greater energy metabolism is expected to lower oxidative stress in the brain, making more energy available to protect and…
Researchers with IBM and the Michael J. Fox Foundation developed a computational model that may help physicians better understand how Parkinson’s disease will progress among individuals. In their study, the algorithm — based on a branch of computer science called machine learning — identified groups of Parkinson’s symptoms and…
Get regular updates to your inbox.
